Novo Nordisk (NVO) shares rallied more than 6% today after the Food and Drug Administration (FDA) approved Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH).
Investors are cheering NVO shares also because the pharma giant said cash-paying U.S. customers can now access its blockbuster diabetes drug, Ozempic, at a massive discount ($499 per month).
